Upcoming Events

The Genome Writers Guild is a scientific organization of researchers, physicians, students, entrepreneurs, investors, government representatives, futurists, artists and the public. It is built on an understanding that genomic engineering comprises powerful technologies that have the potential to better humanity and the world humans inhabit.

The specific goal for this meeting is to foster fruitful and creative interactions between researchers interested in applying these systems to genome engineering and related advances in a wide variety of organisms, together with scientists studying the basic biology of CRISPR and related bacterial defense systems.

Discovery on Target (DOT) is the industry’s preeminent event on novel drug targets and technologies for drug discovery professionals. DOT highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules.

Fueled by the rapid advancements in both epigenetic research as well as translational gene editing and gene therapy, the EpiBio conferences were established in 2017 as a platform for synthetic biologists developing tools for epigenetic reprogramming.

The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy, and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.

Burgeoning knowledge about the RNA world is opening up new opportunities to understand disease and develop therapeutic and diagnostic interventions. As RNA therapeutics continue to change the face of clinical practice, this conference explores progress in our understanding of the numerous roles of RNAs in cellular functions and diseases and efforts to translate advances in basic science into safer and more efficacious therapies, with a particular emphasis this year on clinical advances in cardiovascular and metabolic disease.